Patents Assigned to Kura Oncology, Inc.
  • Methods for treating hematological malignancies and Ewing's sarcoma
    Patent number: 11944627
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 2, 2024
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Francis Burrows, Linda V. Kessler, Liansheng Li, Pingda Ren, Yi Wang, Tao Wu, Jingchuan Zhang
  • Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
    Patent number: 11672774
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: June 13, 2023
    Assignee: Kura Oncology, Inc.
    Inventors: Francis Burrows, Yi Liu
  • Substituted inhibitors of menin-MLL and methods of use
    Patent number: 11673898
    Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: June 13, 2023
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
  • Substituted inhibitors of menin-MLL and methods of use
    Patent number: 11649251
    Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: May 16, 2023
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Tao Wu, Liansheng Li, Pingda Ren
  • Bridged bicyclic inhibitors of menin-MLL and methods of use
    Patent number: 11555041
    Abstract: The present disclosure provides compounds of Formula (I-A) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: January 17, 2023
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 11541045
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: January 3, 2023
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Synthesis of tipifarnib
    Patent number: 11542244
    Abstract: Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: January 3, 2023
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Pingda Ren, Xiaohu Deng, Wanping Mai
  • Methods and compositions for inhibiting the interaction of menin with MLL proteins
    Patent number: 11542248
    Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 3, 2023
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu, Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 11291663
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: April 5, 2022
    Assignee: Kura Oncology, Inc.
    Inventor: Antonio Gualberto
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 11207314
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 28, 2021
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20210381063
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 9, 2021
    Applicant: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 11124839
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 21, 2021
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • SYNTHESIS OF TIPIFARNIB
    Publication number: 20210246114
    Abstract: Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.
    Type: Application
    Filed: May 17, 2019
    Publication date: August 12, 2021
    Applicant: KURA ONCOLOGY, INC.
    Inventors: Pingda REN, Xiaohu DENG, Wanping MAI
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 10980793
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: April 20, 2021
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 10806730
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 20, 2020
    Assignee: Kura Oncology, Inc.
    Inventor: Antonio Gualberto
  • Substituted inhibitors of menin-MLL and methods of use
    Patent number: 10781218
    Abstract: The present disclosure provides compounds of Formula (II-A), which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: September 22, 2020
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
  • Bridged bicyclic inhibitors of menin-MLL and methods of use
    Patent number: 10752639
    Abstract: The present disclosure provides compounds of Formula (I-E) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: August 25, 2020
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
  • Methods and compositions for inhibiting the interaction of menin with MLL proteins
    Patent number: 10588907
    Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 17, 2020
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 10471055
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: November 12, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: RE49687
    Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: October 10, 2023
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu